Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -848.19% is 128% below its 2-year average of -372.08%, near the low end of its 2-year range (-848.19%–-2.11%).
As of the fiscal period ended Wednesday, December 31, 2025. 52.26% below its 12-month average of -557.06%.
Annual fiscal-year EBITDA margin; no daily interpolation. Historical series through 2025-12-31.
EBITDA MARGIN
-848.19%
EBITDA MARGIN AVG TTM
-557.06%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-52.26%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
YD Bio Limited Ordinary Shares
Market Cap
$435.61M
EBITDA Margin
-848.19%
TTM Avg
-557.06%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.07M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
Market Cap
$431.97M
EBITDA Margin
-14.39%
TTM Avg
-19.65%
3Y Avg
-40.36%
5Y Avg
-40.72%
Market Cap
$439.55M
EBITDA Margin
-16.58%
TTM Avg
-87.69%
3Y Avg
-357.20%
5Y Avg
-653.36%
Market Cap
$442.34M
EBITDA Margin
-581.07%
TTM Avg
-5703.26%
3Y Avg
-7497.20%
5Y Avg
-5095.34%
Market Cap
$426.51M
EBITDA Margin
-211.30%
TTM Avg
-107.34%
3Y Avg
-56928.13%
5Y Avg
-38010.77%
Market Cap
$445.71M
EBITDA Margin
-184.73%
TTM Avg
-138.06%
3Y Avg
-2467.18%
5Y Avg
-2497.88%
Market Cap
$424.10M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | -848.19% | -557.06% | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | -14.39% | -19.65% | -40.36% | -40.72% |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | -16.58% | -87.69% | -357.20% | -653.36% |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | -581.07% | -5703.26% | -7497.20% | -5095.34% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | -211.30% | -107.34% | -56928.13% | -38010.77% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | -184.73% | -138.06% | -2467.18% | -2497.88% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 0.24% | -1.36% | -6.49% | -5.53% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | -4.75% | -133.22% | -117.53% | -82.53% |
Gross Margin
-7.1%
EBITDA Margin
-848.2%
Operating Margin
-883.3%
Net Margin
-1392.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -848.19% |
| 2024-12-31 | -265.93% |
| 2023-12-31 | -2.11% |
